Amneal Pharmaceuticals (AMRX) Gains from Sales and Divestitures (2019)

Amneal Pharmaceuticals (AMRX) recorded quarterly Gains from Sales and Divestitures of $479299.0 in Q4 2019.

Amneal Pharmaceuticals (AMRX) Gains from Sales and Divestitures (2019) Analysis & Trends

Amneal Pharmaceuticals' Gains from Sales and Divestitures history runs 1 years deep, the most recent figure standing at $479299.0 for Q4 2019.

  • In Q4 2019, Gains from Sales and Divestitures changed N/A year-over-year to $479299.0; the TTM figure through Dec 2019 stood at $479299.0 (changed N/A YoY), while the FY2019 annual figure was $479299.0, changed N/A from the prior year.
  • Gains from Sales and Divestitures was $479299.0 for Q4 2019 at Amneal Pharmaceuticals.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $479299.0 in Q4 2019 to a low of $479299.0 in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Amneal Pharmaceuticals 4.66 Bn 4.65 Bn 320.11 Mn

Historic Data

Download Data
DateValue
Dec 31, 2019 479,299.00
Dec 31, 2019 479,299.00